TLX
Telix Pharmaceuticals Limited
NASDAQ: TLX · HEALTHCARE · BIOTECHNOLOGY
$10.43
-0.10% today
Updated 2026-04-29
Market cap
$3.53B
P/E ratio
—
P/S ratio
4.40x
EPS (TTM)
$-0.02
Dividend yield
—
52W range
$6 – $19
Volume
0.3M
Telix Pharmaceuticals Limited (TLX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 1999 | 2000 | 2011 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $23.48M | $20.95M | $28.34M | $32.32M | $29.40M | $31.77M | $195142.00 | $3.48M | $5.21M | $7.60M | $160.10M | $502.55M | $783.21M | $1.21B |
| Revenue growth (YoY) | — | — | — | -10.8% | +35.3% | +14.1% | -9.0% | +8.0% | -99.4% | +1685.9% | +49.6% | +45.7% | +2007.6% | +213.9% | +55.8% | +53.9% |
| Cost of revenue | — | — | $40.63M | $16.31M | $22.62M | $24.86M | $21.35M | $3793.00 | $16.08M | $15.36M | $22.09M | $37.36M | $130.76M | $188.16M | $273.53M | $565.20M |
| Gross profit | — | — | $-17.15M | $4.63M | $5.71M | $7.46M | $8.05M | $-3793.00 | $195142.00 | $-11.88M | $-16.88M | $-29.77M | $29.34M | $314.39M | $509.68M | $640.23M |
| Gross margin | — | — | -73.0% | 22.1% | 20.2% | 23.1% | 27.4% | -0.0% | 100.0% | -340.7% | -323.7% | -391.9% | 18.3% | 62.6% | 65.1% | 53.1% |
| R&D | — | — | — | — | — | $62000.00 | $10000.00 | $2.98M | $18.69M | $21.16M | $23.09M | $34.13M | $57.86M | $128.84M | $121.03M | $256.82M |
| SG&A | — | — | $7.83M | $8.09M | $10.66M | $54000.00 | $20000.00 | $2.46M | $8.50M | $11.28M | $18.01M | $34.92M | $49.13M | $78.98M | $121.65M | $237.15M |
| Operating income | $-578000.00 | $-994000.00 | $-35443.00 | $-1.91M | $-5.07M | $-116000.00 | $-30000.00 | $-6.37M | $-15.68M | $-40.26M | $-49.25M | $-81.25M | $-91.93M | $51.89M | $82.13M | $26.64M |
| Operating margin | — | — | -0.2% | -9.1% | -17.9% | -0.4% | -0.1% | -20.0% | -8037.7% | -1155.1% | -944.8% | -1069.6% | -57.4% | 10.3% | 10.5% | 2.2% |
| EBITDA | $-578000.00 | $-994000.00 | $4.51M | $1.64M | $-1.40M | $-16000.00 | $-14000.00 | $-6.77M | $-25.82M | $-24.48M | $-44.94M | $-70.07M | $-92.84M | $22.97M | $98.23M | $79.83M |
| EBITDA margin | — | — | 19.2% | 7.8% | -5.0% | -0.0% | -0.0% | -21.3% | -13231.3% | -702.4% | -862.1% | -922.5% | -58.0% | 4.6% | 12.5% | 6.6% |
| EBIT | — | — | $-35443.00 | $-1.91M | $-5.07M | $-132000.00 | $-44000.00 | $-6.77M | $-25.83M | $-28.71M | $-49.25M | $-75.25M | $-98.22M | $16.22M | $92.55M | $47.17M |
| Interest expense | — | — | $1.36M | $333673.00 | $279192.00 | $419640.00 | $518962.00 | $9401.00 | $29018.00 | $2.41M | $1.18M | $189000.00 | $406000.00 | $13.56M | $21.46M | $55.06M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-289000.00 | $-497000.00 | $-2.54M | $-2.51M | $5.43M | $-132000.00 | $-44000.00 | $-6.38M | $-13.83M | $-27.87M | $-44.89M | $-80.51M | $-104.08M | $5.21M | $49.92M | $-10.69M |
| Net income growth (YoY) | — | -72.0% | -411.9% | +1.5% | +316.9% | -102.4% | +66.7% | -14393.4% | -116.9% | -101.5% | -61.1% | -79.4% | -29.3% | +105.0% | +858.0% | -121.4% |
| Profit margin | — | — | -10.8% | -12.0% | 19.2% | -0.4% | -0.1% | -20.1% | -7087.1% | -799.6% | -861.1% | -1059.9% | -65.0% | 1.0% | 6.4% | -0.9% |